POSTCOVID COMPLICATIONS IN UROLOGY. PREVENTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

COVID-19 is one of the biggest challenges facing medics and scientists around the world in the modern era. Despite the fact that considerable efforts have been made to treat COVID-19, the interaction of the virus with various organs and systems of the human body is still insufficiently studied. According to a number of authors, the clinical manifestations of COVID-19 can be represented not only by symptoms of damage to the respiratory system, but also by urogenital complications, in particular from the prostate gland. This article discusses the mechanisms of action of the SARS-CoV-2 virus on age-related patients with chronic prostatitis and/or benign prostatic hyperplasia, as well as ways to prevent the progression of prostate diseases caused by this virus.

Full Text

Restricted Access

About the authors

A. V Kuzmenko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

Email: kuzmenkoav09@yandex.ru
Ph.D., MD, professor, professor at the Department of Specialized Surgical disciplines Voronezh, Russiа

V. V Kuzmenko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

Email: kuzmenkovv2003@mail.ru
Ph.D., MD, professor, professor at the Department of Specialized Surgical disciplines Voronezh, Russiа

T. A Gyaurgiev

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

Email: tima001100@mail.ru
Ph.D., associate professor at the Department of Specialized Surgical disciplines Voronezh, Russiа

References

  1. Hui D.S., I Azhar E., Madani T.A., Ntoumi F., Kock R., Dar O., et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China.Int J Infect Dis 2020;91: 264-266. doi: 10.1016/j.ijid.2020.01.009.
  2. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report - 51 [Internet]. 11 March 2020. Available at: https://www.who.int/docs/defaultsource/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10. Accessed March 2020
  3. Zumla A., Chan J.F., Azhar E.I., Hui D.S., Yuen K.Y. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15(5):327- 347. doi: 10.1038/nrd.2015.37.
  4. He F., Deng Y., Li W. Coronavirus Disease 2019: what we know? J Med Virol 2020 [Epub ahead of print]. doi: 10.1002/jmv.25766
  5. Yang Y., Peng F., Wang R., Guan K., Jiang T., Xu G., et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020; 102434 [Epub ahead of print]. doi: 10.1016/j.jaut.2020.102434.
  6. Zumla A., Niederman M.S. The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security. Curr Opin Pulm Med 2020;26(3):193-196. doi: 10.1097/MCP.0000000000000676.
  7. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 [Epub ahead of print]. doi: 10.1001/jama.2020.1585
  8. Gu J., Han B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158:1518-1519.
  9. Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection - a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020;9(1):727-732. doi: 10.1080/22221751.2020.1746199.
  10. Zou X., Chen K., Zou J., Han P., Hao J., Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020;14(2):185-192. doi: 10.1007/s11684-020-0754-0
  11. Yang X.H., Sun R.H., Chen D.C. [Diagnosis and treatment ofCOVID-19: acute kidney injury cannot be ignored] [Article in Chinese]. Zhonghua Yi Xue Za Zhi 2020;100(16):1205-1208. doi: 10.3760/cma.j.cn112137-20200229-00520. Chinese.
  12. Fan С., Li K., Ding Ya., Lu W.L., Wang J. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection. MedRxiv 2020. Doi: https://doi.org/10.1101/2020.02.12.20022418.
  13. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhi bitor. Cell. 2020;181:271-280.e8.
  14. Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.Int J Oral Sci. 2020;12:1-5.
  15. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа; 2018. 480 с.
  16. Gravas S., Cornu J.N, Drake M.J. et al. EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2018. Available at: http://uroweb.org/guideline/treatment-of-non-neurogenic male-luts/ Accessed 5 May 2019
  17. Schaeffer A.J. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis. Urology. 2002;60(6 Suppl):5-6; discussion 6-7. doi: 10.1016/s0090-4295(02)02292-6.
  18. Kudryavcev Yu.V., SivkovA.V. Morphological alteration in benign prostatic hyperplasia tissue. Experimental and clinical urology. 2010;1:8-22 Russian (Кудрявцев Ю.В., Сивков А.В. Морфологические изменения в ткани предстательной железы при доброкачественной гиперплазии. Экспериментальная и клиническая урология. 2010;1:8-22.)
  19. Berry, S.J., Coffey, D.S., Walsh, P.C. and Ewing, L.L. (1984) The Development of Human Benign Prostatic Hyperplasia with Age. The Journal of Urology, 132, 474-479. https://doi.org/10.1016/S0022-5347(17)49698-4
  20. Roehrborn C.G., Oyarzabal Perez I., Roos E.P., Calomfirescu N., Brotherton B., Wang F., Palacios J.M., Vasylyev A., Manyak M.J. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;7. doi: 10.1111/bju.13033
  21. Li L. Q, Huang T., Wang Y. Q, Wang Z.P., Liang Y., Huang T.B., et al. COVID-patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92:577-583.
  22. Liang X. Is COVID-19 more severe in older men? Postgrad Med J. 2020;96:426.
  23. Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eur Surveill. 2020;25:2000180.
  24. Nishiura H., Kobayashi T., Miyama T., Suzuki A., Jung S.-m., Hayashi K., et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).Int J Infect Dis. 2020;94:154-155.
  25. Can O, Erkoç M, Ozer M, Umeyir Karakanli M, Otunctemur A. The effect of COVID-19 on lower urinary tract symptoms in elderly men.Int J Clin Pract. 2021;75:e14110.
  26. Kaya Y., Kaya C., Kartal T., Tahta T., Tokgöz V.Y. Could LUTS beearly symptoms of COVID-19.Int J Clin Pract. 2020;75:e13850.
  27. Cohn JN. Role of the renin-angiotensin system in cardiovascular disease. Cardiovasc Drugs Ther. 2010;24:341-344.
  28. Peach MwJ. Renin-angiotensin system: biochemistry and mechan isms of action. Physiol Rev. 1977;57:313-70.
  29. Dinh D.T., Frauman A.G., Sourial M., Casley D.J., Johnston C.I., Fabiani M.E. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology. 2001;142:1349-1356.
  30. Nassis L., Frauman A.G., Ohishi M., Zhuo J., Casley D.J., Johnston C.I., et al. Localization of angiotensin-converting enzyme in the human prostate: pathological expression in benign prostatic hyperplasia. J Pathol. 2001;195:571-9.
  31. Dinh D.T., Frauman A.G., Somers G.R., Ohishi M., Zhou J., Casley D.J., et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT1 receptor expression in benign prostatic hyperplasia. J Pathol. 2002;196:213-9.
  32. Singh Y., Gupta G., Sharma R., Matta Y., Mishra A., Pinto Td.J.A., et al. Embarking effect of ACE2-angiotensin 1-7/mas receptor axis in benign prostate hyperplasia. Crit Rev Eukaryot Gene Expr. 2018;28:115-24.
  33. Guy J.L., Jackson R.M., Acharya K.R., Sturrock E.D., Hooper N.M., Turner A.J. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry. 2003;42:13185-13192.
  34. Mizuiri S., Ohashi Y. ACE and ACE2 in kidney disease. World J Nephrol. 2015;4:74-82.
  35. Santos R.A., Ferreira A.J., Simoes e Silva A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol. 2008;93:519-527.
  36. Silveira K.D., Barroso L.C., Vieira A.T., Cisalpino D., Lima C.X., Bader M., et al. Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin induced nephropathy. PLoS ONE. 2013;8:e66082.
  37. Chughtai B., Lee R., Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150.
  38. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Баранников И.И. Хронобиологический статус больных с хроническим простатитом на фоне аденомы простаты. Системный анализ и управление в биомедицинских системах. 2017;16(3):513-516.
  39. Kramer G., Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol. 2006;16: 25-29.
  40. Theyer G., Kramer G., Assmann I., Sherwood E., Preinfalk W., Marberger M., et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest.1992;66:96.
  41. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Энтомологический препарат аденопросин в лечении пациентов с доброкачественной гиперплазией предстательной железы и хроническим простатитом. Урология. 2021;1:39-44.
  42. Карякин Н.Н., Костина О.В., Галова Е.А., Поповичева А.Н., Соснина Л.Н., Преснякова М.В., Макарова Е.В., Туличев А.А. Нарушения реологических свойств эритроцитов у пациентов с COVID-19. Медицинский альманах. 2020;3(64).
  43. Iba T., Levy J.H., Levi M., Connors J.M., Thachil J. Coagulopathy of coronavirus disease 2019 [published online ahead of print, 2020 May 27]. Crit Care Med 2020; https://doi.org/10.1097/CCM.0000000000004458
  44. Marchandot B., Sattler L., Jesel L., Matsushita K., Schini-Kerth V., Grunebaum L., Morel O. COVID 19 related coagulopathy: a distinctentity? J Clin Med 2020;9(6):E1651, https://doi.org/10.3390/jcm9061651
  45. Giannis D., Ziogas I.A., Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020;127:104362, https://doi.org/10.1016/j.jcv.2020.104362
  46. Морозов В.Г., Хавинсон В.Х. Новый класс биологических регуляторов многоклеточных систем - цитомедины. Успехи совр. биологии. 1983;96(6):339-352.
  47. Аль-Шукри С.Х., Кузьмин И.В., Горбачев А.Г. Простатические пептидные биорегуляторы в лечении урологических болезней. Пособие для врачей. СПб., 2011.
  48. Кузьмин И.В. Витапрост форте в лечении больных доброкачественной гиперплазией предстательной железы: патогенетические основы и клинические результаты. Урология. 2019;4:141147.
  49. Ткачук В.Н., Ткачук И.Н. Эффективность витапроста у больных хроническим простатитом. Урология. 2012;4:88-91.
  50. Лопаткин Н.А., Камалов А.А., Мазо Е.Б., Охотобов Д.А. Применение таблеток препарата Витапроста для профилактики обострений хронического абактериального простатита. Урология. 2009;1:29-35.
  51. Камалов А.А., Ефремов Е.А., Дорофеев С.Д., Панюшкин С.М. Применение пероральной формы препарата Витапроста® в лечении хронического абактериального простатита. Урология. 2006;5:45-51.
  52. Мазо Е.Б., Кривобородов Г.Г., Суханов С.В. и др. Эффективность и безопасность новой лекарственной формы препарата витапроста, таблетки, в терапии пациентов с аденомой предстательной железы. Урология. 2007;6:55-60.
  53. Ткачук В.Н., Ткачук И.Н., Боровец С.Ю. Результаты 12-летнего исследования эффективности витапроста у больных хроническим простатитом. Урологические ведомости. 2016;6(4):5-9 URL: https://cyberleninka.ru/article/n/rezultaty-12-letnego-issledovaniya-effektivnosti-vitaprosta-u-bolnyh-hronicheskim-prostatitom
  54. Миллер А.М., Ярошенко В.П., Сорока П.В., Стахнев Е.Ю. Эффективность витапроста форте у больных аденомой предстательной железы. Урология. 2008;5:50-54.
  55. Ситдыкова М. Э., Зубков А.Ю. Эффективность препарата витапрост форте в лечении аденомы предстательной железы. Урология. 2009;6:27-29.
  56. Камалов А.А., Ефремов Е.А., Дорофеев С.Д. и др. Витапрост форте в лечении больных с аденомой простаты. Урология. 2007;3:39-47.
  57. Лопаткин Н.А., Камалов А.А., Мазо Е.Б., Охотобов Д.А. Применение таблеток препарата Витапроста для профилактики обострений хронического абактериального простатита. Урология. 2009;1:29-35.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies